The stock of Catalyst Pharmaceuticals Inc (CPRX) has gone up by 9.25% for the week, with a 3.54% rise in the past month and a 13.55% rise in the past quarter. The volatility ratio for the week is 8.16%, and the volatility levels for the past 30 days are 4.12% for CPRX. The simple moving average for the last 20 days is 6.42% for CPRX stock, with a simple moving average of 22.87% for the last 200 days.
Is It Worth Investing in Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Right Now?
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has a price-to-earnings ratio that is above its average at 19.45x. The stock has a 36-month beta value of 0.80. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CPRX is 105.46M, and at present, short sellers hold a 5.63% of that float. On January 10, 2025, the average trading volume of CPRX was 917.06K shares.
CPRX) stock’s latest price update
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has seen a rise in its stock price by 16.74 in relation to its previous close of 19.53. However, the company has experienced a 9.25% gain in its stock price over the last five trading sessions. zacks.com reported 2025-01-09 that Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug’s exclusivity in the United States till Feb. 25, 2035.
Analysts’ Opinion of CPRX
Many brokerage firms have already submitted their reports for CPRX stocks, with Stephens repeating the rating for CPRX by listing it as a “Overweight.” The predicted price for CPRX in the upcoming period, according to Stephens is $35 based on the research report published on November 18, 2024 of the previous year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see CPRX reach a price target of $27. The rating they have provided for CPRX stocks is “Buy” according to the report published on March 14th, 2024.
BofA Securities gave a rating of “Buy” to CPRX, setting the target price at $23 in the report published on March 07th of the previous year.
CPRX Trading at 4.81% from the 50-Day Moving Average
After a stumble in the market that brought CPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.06% of loss for the given period.
Volatility was left at 4.12%, however, over the last 30 days, the volatility rate increased by 8.16%, as shares surge +4.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.24% upper at present.
During the last 5 trading sessions, CPRX rose by +9.25%, which changed the moving average for the period of 200-days by +44.95% in comparison to the 20-day moving average, which settled at $21.42. In addition, Catalyst Pharmaceuticals Inc saw 9.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CPRX starting from Miller Steve, who sale 50,000 shares at the price of $21.93 back on Dec 10 ’24. After this action, Miller Steve now owns 686,996 shares of Catalyst Pharmaceuticals Inc, valued at $1,096,350 using the latest closing price.
Miller Steve, the Officer of Catalyst Pharmaceuticals Inc, proposed sale 50,000 shares at $21.93 during a trade that took place back on Dec 10 ’24, which means that Miller Steve is holding shares at $1,096,333 based on the most recent closing price.
Stock Fundamentals for CPRX
Current profitability levels for the company are sitting at:
- 0.38 for the present operating margin
- 0.82 for the gross margin
The net margin for Catalyst Pharmaceuticals Inc stands at 0.31. The total capital return value is set at 0.26. Equity return is now at value 28.29, with 24.10 for asset returns.
Based on Catalyst Pharmaceuticals Inc (CPRX), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 77.74.
Currently, EBITDA for the company is 119.69 million with net debt to EBITDA at -2.28. When we switch over and look at the enterprise to sales, we see a ratio of 4.95. The receivables turnover for the company is 7.9for trailing twelve months and the total asset turnover is 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.11.
Conclusion
To sum up, Catalyst Pharmaceuticals Inc (CPRX) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
